[Clinical studies on Suncefal (cefpiramide) concentration in prostatic tissue and bladder wall]

Area of Science:

• Pharmacokinetics and Drug Distribution
• Antimicrobial Agents

Context:

• Benign prostatic hypertrophy (BPH) and bladder tumors are common conditions requiring surgical intervention.
• Postoperative infections are a significant risk in urological surgeries.
• Understanding antibiotic penetration into target tissues is crucial for effective prophylaxis and treatment.

Purpose:

• To quantify cefpiramide (CPM) concentrations in human prostatic tissue and bladder wall following intravenous administration.
• To determine the pharmacokinetic profile of CPM in these specific tissues.
• To evaluate the potential of CPM as an effective antibiotic for preventing postoperative infections in urological procedures.

Summary:

• Following a 2g intravenous bolus dose of cefpiramide (CPM), concentrations in prostatic tissue ranged from 28.4 to 131 µg/g, with a tissue-to-serum ratio of 0.15-0.63 over 12-220 minutes.
• The elimination half-life (T1/2) of CPM in prostatic tissue was determined to be 3.29 hours.
• High CPM levels were observed in the bladder wall, and both prostatic and bladder tissue concentrations exceeded the minimum inhibitory concentrations (MICs) for frequently isolated bacteria from infected sites.

Impact:

• Cefpiramide demonstrates excellent penetration into prostatic and bladder tissues.
• Achieved tissue concentrations support the efficacy of CPM in combating potential pathogens.
• CPM is a promising antibiotic for prophylaxis and treatment of postoperative infections in urological surgery.